Uterine Relaxants
Uterine Relaxants - Related Videos
08:02
Mouse Model of Surgically-induced Endometriosis by Auto-transplantation of Uterine Tissue
0 Views •
Cited by 62 •
2012
A description of the surgical induction of endometriosis in mice and rats by auto-transplantation of uterine tissue to the arterial cascade of the intestinal mesentery.
01:16
Uterine Tubes
0 Views •
2024
The uterine or fallopian tubes function as the conduit through which oocytes travel from the ovaries to the uterus. Each fallopian tube measures approximately 10 to 13 cm long and is anatomically divided into the infundibulum, ampulla, isthmus, and interstitial part (or intramural segment). The infundibulum is characterized by its funnel shape and features extensions called fimbriae which reach towards the peritoneal cavity. These fimbriae play a critical role during ovulation as they extend...
01:29
Relaxation of Skeletal Muscles
0 Views •
2024
The period of muscle contraction primarily influences the duration of stimulation at the neuromuscular junction (NMJ), the presence of free calcium ions in the sarcoplasm, and the availability of energy or ATP to support contractions. When an action potential reaches the axon terminal, it depolarizes the membrane and opens voltage-gated sodium channels. Sodium ions enter the cell, further depolarizing the presynaptic membrane. This depolarization causes voltage-gated calcium channels to open.
07:51
Mesenteric Artery Contraction and Relaxation Studies Using Automated Wire Myography
0 Views •
Cited by 37 •
2011
An automated myography method for force measurements in isolated mesenteric arteries is described. It employs a Mulvany-Halpern Auto Dual Wire Myograph 510A to determine responses to phenylephrine and extracellular calcium. The method allows consistent determination of isometric responses to agonists in small vessels of diameters of 60 - 300 μm, independently.
01:28
Classification of Skeletal Muscle Relaxants
0 Views •
2023
Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics. Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
FAQs
β2-adrenergic stimulation increases cyclic AMP within uterine smooth muscle cells. This signaling change opposes the cellular processes that sustain myometrial contraction, thereby reducing contractile activity. The pathway illustrates why drugs acting at the same receptor can produce uterine relaxation, while their clinical effects still vary with dose, maternal condition, and fetal status.
Calcium entry supports the activation of uterine smooth muscle contraction. Medicines that inhibit this entry reduce the intracellular signal needed for effective contraction, producing relaxation through a mechanism distinct from β2-receptor stimulation. This distinction matters in pharmacology because different drug classes can reach a similar uterine outcome through separate cellular pathways.
Oxytocin receptor blockade prevents oxytocin from activating its normal contraction-promoting pathway in the myometrium. Rather than increasing a relaxation signal, this approach removes an important stimulus for contraction. Its mechanism provides a useful comparison with β2-adrenergic stimulation and calcium-entry inhibition when pharmacologists analyze how uterine activity can be reduced.
The response depends on the specific drug mechanism, dose, maternal condition, and fetal status. These variables can alter both the extent of uterine relaxation and the balance between potential benefit and adverse reactions. Pharmacological decisions therefore require individualized evaluation rather than assuming that all agents, doses, or clinical circumstances will produce equivalent outcomes.
They are used as tocolytics when the therapeutic goal is to delay preterm labor by reducing excessive or premature myometrial activity. The purpose is not simply to suppress contractions in every circumstance, but to apply relaxation where delaying labor may be relevant. Selection still depends on the medicine's mechanism, dose, maternal condition, and fetal status.
In selected clinical situations, these agents may be considered when uterine hypertonicity requires reduction of excessive smooth-muscle activity. Pharmacological assessment weighs the intended relaxation against possible adverse reactions and the status of both mother and fetus. Comparing receptor stimulation, calcium-entry inhibition, and oxytocin-receptor blockade helps explain why treatment choices may differ between situations.